Inter-American Development Bank
facebook
twitter
youtube
linkedin
instagram
Abierto al públicoBeyond BordersCaribbean Development TrendsCiudades SosteniblesEnergía para el FuturoEnfoque EducaciónFactor TrabajoGente SaludableGestión fiscalGobernarteIdeas MatterIdeas que CuentanIdeaçãoImpactoIndustrias CreativasLa Maleta AbiertaMoviliblogMás Allá de las FronterasNegocios SosteniblesPrimeros PasosPuntos sobre la iSeguridad CiudadanaSostenibilidadVolvamos a la fuente¿Y si hablamos de igualdad?Home
Citizen Security and Justice Creative Industries Development Effectiveness Early Childhood Development Education Energy Envirnment. Climate Change and Safeguards Fiscal policy and management Gender and Diversity Health Labor and pensions Open Knowledge Public management Science, Technology and Innovation  Trade and Regional Integration Urban Development and Housing Water and Sanitation
  • Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer

Gente Saludable

IDB

  • HOME
  • CATEGORIES
    • Aging and Dependency
    • Courses and Seminars
    • Digital Transformation
    • Public health and nutrition
    • Healthy Lifestyle
    • Health services
    • Health Spending and Financing
    • Women’s and Children’s Health
  • authors
  • English
    • Spanish
    • Portuguese

How Much Could Chilean Households Save by Switching to Generic Drugs?

June 27, 2024 por Pamela Góngora Leave a Comment


In Latin America and the Caribbean, pharmaceutical expenditure ranges from 8.5% (Costa Rica) to 22.1% (Mexico) of total health expenditure. Although governments bear part of this expenditure, in many of the region’s countries households assume a significant proportion. In Chile, for example, health spending directly paid by households accounts for 32% of total health spending, and spending on medicines is the main component of out-of-pocket spending, accounting for 40%.

How can this burden be reduced? Substitution towards generic drugs may be one solution. 

What Are Generic Drugs?

Generic drugs are versions of the original drug, with the same active ingredients, which are marketed when the patent on the original has expired and the authorities have certified their quality, safety and efficacy.

Generally, generic drugs, and particularly those that are not branded (marketed under the International Nonproprietary Name), are sold at lower prices than their original or generic branded counterparts.

What Is the Savings Potential Through Generic Drugs?

A study by the Inter-American Development Bank estimates how much Chilean households could save if they were to buy non-branded generic drugs instead of their equivalents. On average, branded drugs are 6 times more expensive than unbranded generic products, and can be up to 35 times more expensive. Given that for 29% of the market there is non-branded generic competition and therefore substitution is possible, these price differences imply that the estimated potential annual savings is US$283.2 million.

For Chilean households, these savings represent 0.4% of total household spending, 3.8% of out-of-pocket spending on health and 10.3% of out-of-pocket spending on medicines. This saving would allow households, for example, to pay for about two months of transportation per year. In households with lower levels of education, substitution to generics could reduce outpatient drug spending even further, by 12% to 18%.

Another way to visualize the magnitude of these savings id the following: The US$283.2 million mentioned above would be enough to lift 223,239 Chilean households out of extreme poverty. Moreover, the potential savings could be much greater if unbranded generic versions of all off-patent drugs were marketed in Chile. Indeed, the study found that 62% of the total market value could count on unbranded generic competition, but still does not. 

A health system that seeks to move towards Universal Health Coverage must strive to reduce out-of-pocket household spending. One strategy in this direction is to encourage the demand for and supply of non-branded generic drugs, which tend to be much less expensive than their branded alternatives. 

Various policies can encourage competition through regulatory and pricing incentives, including physician commitment to prescribing international nonproprietary names, the possibility of substitution to generics at the point of dispensing, and user education and awareness of the benefits of using nonbranded generics.

Learn more strategies and tools for more efficient healthcare spending in our publication Smart Spending for Health: How to Make Each Dollar Count – download it now!

Interested in learning more? Register for this webinar here

Filed Under: Health Spending and Financing Tagged With: generic drugs, health, IDB, Inter-American Development Bank, non-branded drugs, políticas públicas, public policy

Pamela Góngora

Senior Associate in the Social Protection and Health Division of the IDB, with more than fifteen years of experience in health economics and policy, with special emphasis on health prioritization, economic evaluations and interventions focused on reducing the burden of non-communicable diseases. Pamela is an Economist, Master in Economic Policy and Master in Social Policy and Planning from the University of London. She also completed a PhD in Population Health/Health Economic Evaluation at the University of Oxford (UK). In the past, Pamela has worked as a project manager and economic studies in the private sector, as an advisor to the Colombian Minister of Health and as an independent consultant in health program evaluation.

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Follow Us

Subscribe

Search

Health

Latin American and Caribbean countries face multiple challenges to provide quality healthcare for their citizens. In this blog, IDB Specialists and international experts discuss current health issues and hope to build a dynamic dialogue through your comments.

Similar Posts

  • Is it possible to achieve more health per dollar spent? Potential gains by improving health spending efficiency
  • Top 5 of Gente Saludable: The Most Read of 2024
  • Can We Afford a Healthy Future? 
  • The Hidden Trade-off of High-Cost Drugs
  • 10 Take-Aways on How the Region Can Improve Health Spending Efficiency

Footer

Banco Interamericano de Desarrollo
facebook
twitter
youtube
youtube
youtube

    Blog posts written by Bank employees:

    Copyright © Inter-American Development Bank ("IDB"). This work is licensed under a Creative Commons IGO 3.0 Attribution-NonCommercial-NoDerivatives. (CC-IGO 3.0 BY-NC-ND) license and may be reproduced with attribution to the IDB and for any non-commercial purpose. No derivative work is allowed. Any dispute related to the use of the works of the IDB that cannot be settled amicably shall be submitted to arbitration pursuant to the UNCITRAL rules. The use of the IDB's name for any purpose other than for attribution, and the use of IDB's logo shall be subject to a separate written license agreement between the IDB and the user and is not authorized as part of this CC- IGO license. Note that link provided above includes additional terms and conditions of the license.


    For blogs written by external parties:

    For questions concerning copyright for authors that are not IADB employees please complete the contact form for this blog.

    The opinions expressed in this blog are those of the authors and do not necessarily reflect the views of the IDB, its Board of Directors, or the countries they represent.

    Attribution: in addition to giving attribution to the respective author and copyright owner, as appropriate, we would appreciate if you could include a link that remits back the IDB Blogs website.



    Privacy Policy

    Derechos de autor © 2025 · Magazine Pro en Genesis Framework · WordPress · Log in

    Banco Interamericano de Desarrollo

    Aviso Legal

    Las opiniones expresadas en estos blogs son las de los autores y no necesariamente reflejan las opiniones del Banco Interamericano de Desarrollo, sus directivas, la Asamblea de Gobernadores o sus países miembros.

    facebook
    twitter
    youtube
    This site uses cookies to optimize functionality and give you the best possible experience. If you continue to navigate this website beyond this page, cookies will be placed on your browser.
    To learn more about cookies, click here
    X
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT